CN100464743C - 治疗和预防药物中毒的n-乙酰半胱氨酸组合物 - Google Patents

治疗和预防药物中毒的n-乙酰半胱氨酸组合物 Download PDF

Info

Publication number
CN100464743C
CN100464743C CNB028077334A CN02807733A CN100464743C CN 100464743 C CN100464743 C CN 100464743C CN B028077334 A CNB028077334 A CN B028077334A CN 02807733 A CN02807733 A CN 02807733A CN 100464743 C CN100464743 C CN 100464743C
Authority
CN
China
Prior art keywords
acetylcysteine
acetaminophen
therapeutic
use according
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028077334A
Other languages
English (en)
Chinese (zh)
Other versions
CN1507350A (zh
Inventor
莱纳德·A·赫泽恩伯格
S·C·德索萨
J·安德鲁斯
里奥铙雷·A·赫泽恩伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Bioadvantex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26960383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100464743(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioadvantex Pharma Inc filed Critical Bioadvantex Pharma Inc
Publication of CN1507350A publication Critical patent/CN1507350A/zh
Application granted granted Critical
Publication of CN100464743C publication Critical patent/CN100464743C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028077334A 2001-03-30 2002-03-28 治疗和预防药物中毒的n-乙酰半胱氨酸组合物 Expired - Fee Related CN100464743C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28060001P 2001-03-30 2001-03-30
US60/280,600 2001-03-30
US09/833,228 2001-04-11
US09/833,228 US6566401B2 (en) 2001-03-30 2001-04-11 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Publications (2)

Publication Number Publication Date
CN1507350A CN1507350A (zh) 2004-06-23
CN100464743C true CN100464743C (zh) 2009-03-04

Family

ID=26960383

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028077334A Expired - Fee Related CN100464743C (zh) 2001-03-30 2002-03-28 治疗和预防药物中毒的n-乙酰半胱氨酸组合物

Country Status (13)

Country Link
US (2) US6566401B2 (enExample)
EP (1) EP1379232B1 (enExample)
JP (3) JP2005508840A (enExample)
CN (1) CN100464743C (enExample)
AU (1) AU2002255942B2 (enExample)
BR (1) BR0208563A (enExample)
CA (1) CA2442168C (enExample)
ES (1) ES2550094T3 (enExample)
IL (2) IL158181A0 (enExample)
MX (1) MXPA03008904A (enExample)
NZ (1) NZ528478A (enExample)
RU (1) RU2291689C2 (enExample)
WO (1) WO2002078627A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662863B2 (en) * 2003-06-09 2010-02-16 Alan Andrews Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
RU2302236C2 (ru) * 2005-09-09 2007-07-10 Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
EP2291182A1 (en) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Salicylate conjugates useful for treating metabolic disorders
EP2408443A1 (en) * 2009-03-16 2012-01-25 Genmedica Therapeutics SL Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
AU2010224867A1 (en) * 2009-03-16 2011-10-06 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
AU2010248758A1 (en) * 2009-05-15 2011-11-24 Intermune, Inc. Methods of treating HIV patients with anti-fibrotics
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
CN102573463A (zh) * 2009-07-15 2012-07-11 小利兰·斯坦福大学托管委员会 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
WO2013006658A1 (en) * 2011-07-05 2013-01-10 The Brigham And Women's Hospital, Inc. Treatment of acetaminophen-induced liver damage by the administration of modulators of nitric oxide
US8747894B2 (en) 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
EP2854798A4 (en) 2012-05-24 2016-05-11 Mograbi Josef COMPOSITIONS WITH ISOSILYBIN B FOR THE TREATMENT AND PREVENTION OF ACTIVE-INDUCED TOXICITY
TWI816417B (zh) 2013-12-24 2023-09-21 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
WO2016123223A1 (en) * 2015-01-27 2016-08-04 Florengale, Llc Healing topical composition
HK1249035A1 (zh) * 2015-05-27 2018-10-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 降低成像後胰腺炎风险的组合物和方法
EP3302459A4 (en) 2015-05-28 2019-02-20 Baylor College of Medicine ADVANTAGES OF SUPPLEMENT WITH N-ACETYLCYSTEIN AND GLYCIN TO IMPROVE THE GLUTATHION MIRRORS
US11260060B2 (en) 2016-01-11 2022-03-01 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
JP6884420B2 (ja) 2016-02-04 2021-06-09 クザップ リサーチ アンド デベロップメント エルエルシーＣｚａｐ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ， Ｌｌｃ 放出制御及び階層化シクロデキストリン包接体ビヒクル
EP3861994A1 (en) 2016-12-15 2021-08-11 Zambon S.p.A. N-acetylcysteine for use as antibiofilm agent
US11040007B2 (en) * 2017-01-24 2021-06-22 Woosung Pharmaceutical Co., Ltd. Injection composition containing acetaminophen
EP3901620A4 (en) * 2018-12-21 2022-02-16 FUJIFILM Corporation Phototoxicity or photoallergy measurement method and reagent for use in said measurement method
US11590090B2 (en) 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2023010088A1 (en) 2021-07-28 2023-02-02 Pono Lifestyle Colorado, Llc Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, sars-cov-2 spike proteins, and mrna vaccine spike proteins
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US547457A (en) * 1895-10-08 Trolley-track
IT1141406B (it) * 1980-04-01 1986-10-01 Dob Far Spa Sali della cefapirina con aminoacidi
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
DE3616923A1 (de) 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
IT1248995B (it) * 1990-06-26 1995-02-11 Italfarmaco Spa Composizioni farmaceutiche a base di sali ferrosi
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
US5475757A (en) * 1994-06-07 1995-12-12 At&T Corp. Secure data transmission method
AU4399396A (en) * 1994-12-19 1996-07-10 Russinsky Limited Compounds
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
FR2744917B1 (fr) 1996-02-16 1998-04-10 Kouchner Gerard Composition therapeutique a base d'acetaminophene
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
WO1999001118A2 (en) * 1997-07-01 1999-01-14 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
JP2002534397A (ja) * 1999-01-04 2002-10-15 エムエル ラボラトリーズ ピーエルシー 癌の処置のためのｐ４５０／アセトアミノフェンｇｄｅｐｔ
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
. MEDICINALI L'INFORMATORE FARMACEUTICO. 2000 *

Also Published As

Publication number Publication date
JP2015078185A (ja) 2015-04-23
EP1379232A2 (en) 2004-01-14
IL158181A (en) 2012-04-30
MXPA03008904A (es) 2005-03-07
CN1507350A (zh) 2004-06-23
US6566401B2 (en) 2003-05-20
NZ528478A (en) 2007-08-31
JP2011225610A (ja) 2011-11-10
US7723389B2 (en) 2010-05-25
RU2291689C2 (ru) 2007-01-20
US20030069311A1 (en) 2003-04-10
EP1379232A4 (en) 2008-04-23
CA2442168C (en) 2012-05-29
ES2550094T3 (es) 2015-11-04
CA2442168A1 (en) 2002-10-10
AU2002255942B2 (en) 2007-07-05
WO2002078627A2 (en) 2002-10-10
EP1379232B1 (en) 2015-07-29
JP2005508840A (ja) 2005-04-07
WO2002078627A3 (en) 2003-09-18
RU2003131876A (ru) 2005-04-10
IL158181A0 (en) 2004-03-28
BR0208563A (pt) 2006-02-21
US20020142991A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
CN100464743C (zh) 治疗和预防药物中毒的n-乙酰半胱氨酸组合物
AU2002255942A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
Caravati et al. Pediatric cyanide intoxication and death from an acetonitrile-containing cosmetic
EP2453743B1 (en) N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
AR026355A1 (es) Formulacion y metodo antidiabetico.
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
US9238017B2 (en) Compositions with reduced hepatotoxicity
US5248697A (en) Enhancement of glutathione levels with glutamine
RU2003122061A (ru) Антиатеросклеротическая композиция, содержащая каротиноиды, и способ ингибирования окисления липопротеина низкой плотности (ldl)
US20060052455A1 (en) Composition for preventing treating the xepression of clinical symptom in disease caused by mitochondrial dysfunction
US6048540A (en) Acetamenophen composition with reduced liver toxicity
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
US5670549A (en) Prevention and amelioration of liver toxicity with beta-carotene
ZA200307559B (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity.
US20220088044A1 (en) Substances for treatment of coronavirus infection
JP5669111B2 (ja) アラレマイシン又はその誘導体を有効成分とする抗マラリア薬
CN119302961A (zh) 一种含有化合物a的降糖药物组合物
EP4213831A1 (en) Supplement for treatment of coronavirus infection
CS203420B1 (cs) Infúzní roztok k léčení a výživě nemocných s jaterním selháním a hyperaroonámickými stavy
HK1173336A (en) N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Free format text: FORMER OWNER: BIOADVANTEX PHARMA INC.

Effective date: 20120918

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120918

Address after: American California

Patentee after: The Board of Trustees of the Leland Stanford Junior University

Address before: Misi Soja Ann, Canada

Patentee before: Bioadvantex Pharma Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090304

Termination date: 20170328

CF01 Termination of patent right due to non-payment of annual fee